Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
about
Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia AClinical and laboratory approaches to hemophilia aThe "normal" factor VIII concentration in plasma.Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.Treating haemophilia A with recombinant blood factors: a comparison.Monitoring haemophilia severity and treatment: new or old laboratory tests?Thrombin generation and bleeding in haemophilia APotency and mass of factor VIII in FVIII productsChromogenic factor VIII activity assay.Monitoring of modified factor VIII and IX products.The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.A critical appraisal of one-stage and chromogenic assays of factor VIII activity.A comparative study of the effects of temperature, time and factor VIII assay type on factor VIII activity in cryoprecipitate in Iran.Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq(®) ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq(®) ) in adults with severe haemophilia A: efficacy and safety.In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.Activation, activity and inactivation of factor VIII in factor VIII products.Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer.Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience.Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.A novel approach in potential anticoagulants from peptides epitope 558-565 of A2 subunit of factor VIII.A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.Biochemical, molecular and preclinical characterization of a double-virus-reduced human butyrylcholinesterase preparation designed for clinical use.Accuracy of FVIII: C assay by one-stage method can be improved using hemophilic plasma as diluent.International comparative field study of N8 evaluating factor VIII assay performance.The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay.A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards.One-Stage Factor VIII Assays.Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators.Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies.Managing Haemophilia for Life: 5th Haemophilia Global Summit.B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay.Discrepant factor VIII activity in a family with mild haemophilia A and 531 mutation using various FVIII assays and APTT reagents.Variability in factor VIII concentrate measurement: results from SSC field collaborative studies.The endothelial specific isoform of type XVIII collagen correlates to annual bleeding rate in haemophilia patients.
P2860
Q28075081-BAE1C32C-B1DA-467A-8549-E5D5FE0C5A27Q28085355-C64CCA96-29E9-4A06-87C2-200EE52823BBQ34023313-470B89FE-01A1-40CD-9F24-EDD44AF46C22Q35498838-B55E80D7-91CE-42F9-BF68-0DE8F7DAC27BQ35779195-13E355A5-22F5-4159-B1CC-0D22FEFC4E3DQ35915695-13C7FDEB-4640-4974-B7E2-468222567375Q36090217-B4A58FDA-0645-47DD-A007-19251F4EB28CQ37067709-7AE62529-A387-40CD-839F-461A04B968A0Q38200012-F2D06AE0-66FE-458A-95EA-ECC73E298D22Q38206851-53C60546-5162-471C-91F9-79C965027A96Q38286285-3919C402-E9E4-4714-AF6B-F9314CA87C76Q38668506-4742981D-25E7-48E7-9279-BD319049BBE7Q38809730-54BD9B20-4D2F-4002-8DF5-AB57721A0EAEQ38835294-10E9862F-FF25-467D-8ED9-AD67DF95A0C4Q38840145-0710AAEE-122F-4C2D-A33D-FED78A8627CDQ39223784-0C74A172-0A15-4EAC-AC04-DB007EE6F8E0Q39648285-35EC54DB-0751-46A8-A6A7-0A908C4899E9Q39898980-9F0F3E4C-28F4-4D28-A904-E6DD9E5356F8Q40045886-9D35D421-3D56-4AD8-8D17-63806AD4BF2AQ41619223-A482601C-FBFC-4B3B-B94D-05D7729F1C70Q42635432-1F80FAB2-9679-41E1-B043-0B70F97575BEQ42971075-6F6F68A2-9366-4B65-8B76-A767F76764DEQ44608488-C67A985C-11BF-44DD-A9E8-CF98AE3942C0Q45004372-CE67D5F7-232E-42F6-AAAF-E7C27175A4C6Q45372375-4AA55CD3-1E78-451E-8D00-593C40C98E04Q45857738-8574FEDD-5E1A-4CED-A998-01C48FA8A726Q45868601-4809D1AC-16D0-465B-BF20-FE6C867E0243Q45868994-B01FF5C1-48F6-479D-9DA1-C73798F20CA5Q45870324-993CD4B8-E81D-47A1-855A-A0ED05A794E9Q45870711-2FCCCBF7-986C-4CAB-A0BB-A05CDD0C47C0Q45872443-D85B74E1-303B-4015-A769-F27F0FD6F996Q45873800-42269F8E-8B47-4E29-A7F6-2EBF864A6C48Q45879098-23B82D34-D992-44D5-A972-4CB18390CB3DQ45882434-61D83B6C-B553-41E8-8AB1-1CEB15D174A5Q45884519-90107C5C-B814-49D8-8472-91EFEB6838A7Q45885808-0DA0EE76-BCF7-4BE1-B2C7-CAD668CCFE54Q45886444-BE700E88-28A5-4E6E-A02A-F6836FD2EC11Q47663973-73FFAC27-FA27-4A29-BDCA-E4969E351248Q48269941-68646C23-DC9B-48FB-A9A9-5CABEF2BB0DE
P2860
Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Coagulation and chromogenic as ...... dization, and recommendations.
@ast
Coagulation and chromogenic as ...... dization, and recommendations.
@en
Coagulation and chromogenic as ...... dization, and recommendations.
@nl
type
label
Coagulation and chromogenic as ...... dization, and recommendations.
@ast
Coagulation and chromogenic as ...... dization, and recommendations.
@en
Coagulation and chromogenic as ...... dization, and recommendations.
@nl
prefLabel
Coagulation and chromogenic as ...... dization, and recommendations.
@ast
Coagulation and chromogenic as ...... dization, and recommendations.
@en
Coagulation and chromogenic as ...... dization, and recommendations.
@nl
P2093
P356
P1476
Coagulation and chromogenic as ...... dization, and recommendations.
@en
P2093
Anthony R Hubbard
Dawn Sands
Sanjeev Raut
Trevor W Barrowcliffe
P304
P356
10.1055/S-2002-32658
P577
2002-06-01T00:00:00Z